All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Liver kinase B1 (LKB1) is a protein kinase also known as serine/threonine kinase 11 that is encoded by the STK11 gene in humans \[[@pone.0152674.ref001]\]. LKB1 is the homologue of par-4 in non-mammalian species \[[@pone.0152674.ref002]\] and can regulate early embryonic development in both mammals and non-mammals \[[@pone.0152674.ref002]--[@pone.0152674.ref004]\]. LKB1 has been linked to the regulation of epithelial integrity and polarity \[[@pone.0152674.ref005],[@pone.0152674.ref006]\]. The loss of LKB1 disrupts epithelial cell polarity and promotes cancer progression, invasion and metastasis \[[@pone.0152674.ref007],[@pone.0152674.ref008]\]. Experimental evidence also indicates that LKB1 deficiency can cause adenocarcinomas to transdifferentiate into squamous cell carcinomas \[[@pone.0152674.ref009]\]. Therefore, LKB1 is considered a tumor suppressor kinase \[[@pone.0152674.ref010]\].

Studies have demonstrated that low LKB1 protein expression is associated with worse overall survival (OS) in human breast cancer \[[@pone.0152674.ref011]\]. Additionally, low LKB1 expression levels in human pancreatic ductal adenocarcinomas and decreased expression of LKB1 in hepatocellular carcinoma patients are poor prognostic factors \[[@pone.0152674.ref012],[@pone.0152674.ref013]\]. Reports continue to suggest that LKB1 loss at the protein level plays a role in the poor outcomes of patients with colorectal cancer and non-small cell lung cancer \[[@pone.0152674.ref014],[@pone.0152674.ref015]\]. Moreover, studies have also indicated that low expression of LKB1 is associated with tumor clinicopathological features \[[@pone.0152674.ref015],[@pone.0152674.ref016]\].

Although some evidence suggests that decreased LKB1 is an important factor that is implicated in poorer survival in solid tumor patients \[[@pone.0152674.ref011]--[@pone.0152674.ref016]\], some conflicting results have also been reported \[[@pone.0152674.ref017],[@pone.0152674.ref018]\]. However, these results still seem to be controversial. Consequently, we initiated a meta-analysis to determine the significance of decreased LKB1 expression in the prediction of clinical outcomes and to examine the association between decreased LKB1 and the clinicopathological parameters of solid tumors.

Materials and Methods {#sec006}
=====================

Literature Search Strategy {#sec007}
--------------------------

The literature relevant to LKB1 expression and survival in solid tumors was searched in the PubMed, Embase, Web of Science and China National Knowledge Infrastructure (CNKI) databases through October 15, 2015. The search terms included the following key words in various combinations: LKB1, STK11, liver kinase b1, prognosis, prognostic, survival, and overall survival. The list of publications was limited to human studies and restricted to those published in Chinese or English. The references of the review articles and primary research were further searched to identify additional potentially relevant studies to avoid omission due to the electronic search approach.

Study Inclusion and Exclusion Criteria {#sec008}
--------------------------------------

The studies that were included in this meta-analysis met the following criteria: (1) a pathological diagnosis of cancer was made;(2) original published studies with full text that measured LKB1 protein expression in patients with any type of tumor via immunohistochemistry or western blotting; (3) associations of LKB1 expression with overall survival (OS), relapse-free survival (RFS), disease-free survival (DFS), or clinicopathological features were described; (4) hazard ratios (HRs) and 95% confidence intervals (CIs) were reported or could be calculated based on the information in the paper; and (5) when the same author reported repeated results from the same population, the most complete report was included.

The exclusion criteria for this meta-analysis were as follows: (1) unpublished papers; (2) laboratory articles, review and letters; (3) articles with only animal experiments; and (4) studies without information about survival outcomes or survival curves and those in languages other than Chinese and English.

Quality Assessment {#sec009}
------------------

Two independent reviewers (Xi Chen and Xiaoxiao Lu) scored the qualities of the selected papers using the Newcastle---Ottawa Quality Assessment Scale (NOS), which was referenced in a previously published paper \[[@pone.0152674.ref019]\] ([S1 Table](#pone.0152674.s002){ref-type="supplementary-material"}). Briefly, the score of each paper was decided based on selection, comparability and outcome according to the NOS. Each appraised study received a score between 0 and 9. NOS scores of 9--7, 6--4 and 3--1 were defined as high-, intermediate- and low-quality studies, respectively. Discrepancies were discussed until a consensus was reached regarding the final score for each paper.

Data Extraction {#sec010}
---------------

For the eligible studies, two investigators (Ying Gao and Wei Li) independently extracted the following data: first author's name, publication year, region, type of cancer, number of patients, patients' sexes and ages, follow-up times, test methods, staining positions, cut-off values, survival data (including OS, RFS or DFS), analysis method, and clinicopathological parameters, such as tumor differentiation, tumor size/invasion depth, lymph node metastasis and TNM stage. For studies that presented only Kaplan-Meier curves, Engauge Digitizer version 4.1 (<http://digitizer.sourceforge.net/>, a free down-loaded software) was used to extract the survival data. The estimates of the HRs and 95% CIs were calculated by Tierney's method as previously described \[[@pone.0152674.ref020]\]. Subsequently, the raw data were entered into GraphPad Prism 6.0 (GraphPad Software, Inc.) to produce Kaplan-Meier curves for comparison with the published curves \[[@pone.0152674.ref021]\]. Any disagreements were adjudicated by discussion until a consensus was reached.

Statistical Analysis {#sec011}
--------------------

This meta-analysis was performed using Stata 12.0 (Stata Corporation, College Station, TX, USA) software. Generic inverse variance weighting was used to pool the HRs. When the result of a Q-test (I^2^\>50% or P\<0.05) indicated heterogeneity between the studies, the random-effects model was used for the meta-analysis. Otherwise, a fixed-effects model was used \[[@pone.0152674.ref022]\]. An HR greater than 1 indicated poor prognosis in patients with decreased LKB1. The chi-squared test (Cochrane's Q test) and I-squared statistical test were used to analyze the heterogeneity between studies. A sensitivity analysis was used to test the influences of individual studies on the pooled HR to evaluate the stability of the meta-analysis. Because unequal characteristics might have been included in the eligible studies, subgroup stratification analyses were performed according to the testing method, region, cancer type, staining position and analysis method to identify the sources of heterogeneity. Funnel plots were used to graphically represent the publication bias. Begg's (rank correlation) and Egger's (regression asymmetry) tests were adopted to confirm the publication bias.

Pooled estimates of the odds ratios (OR) were calculated using the Mantel-Haenszel method to estimate the correlations of LKB1 expression with the clinicopathological parameters, which included tumor differentiation, tumor size, lymph node metastasis and TNM stage. ORs greater than 1 indicated that decreased LKB1 expression was likely related to poor differentiation, large tumor size (or deep invasion), lymph node metastasis and advanced TNM stage. P-values\<0.05 were considered statistically significant.

Results {#sec012}
=======

Study Search Information {#sec013}
------------------------

The initial search identified one hundred and eleven potentially relevant titles. A further review of the screening results revealed that seventeen studies were of acceptable relevance for retrieval of the full text. However, two of these studies were excluded because the survival curves were based on LKB1 gene expression \[[@pone.0152674.ref023],[@pone.0152674.ref024]\], and one additional study was ruled out because the specimens were metastatic tumors \[[@pone.0152674.ref025]\]. Ultimately, fourteen studies \[[@pone.0152674.ref011]--[@pone.0152674.ref018],[@pone.0152674.ref026]--[@pone.0152674.ref031]\] met the eligibility criteria and were included in the current meta-analysis ([Fig 1](#pone.0152674.g001){ref-type="fig"}).

![Flow diagram of the selection of eligible studies.](pone.0152674.g001){#pone.0152674.g001}

Description of the Studies {#sec014}
--------------------------

The characteristics of the 14 identified studies are shown in Tables [1](#pone.0152674.t001){ref-type="table"} and [2](#pone.0152674.t002){ref-type="table"}. In total, 1915 patients from five regions (China, Taiwan, the USA, France and the UK) were included in these studies. The solid tumors that were included in this meta-analysis were derived from the following seven cancer types: lung adenocarcinomas (or non-small cell lung cancers), breast carcinomas, gastric cancers, hepatocellular carcinomas, pancreatic cancers (or pancreatic ductal adenocarcinomas), colorectal cancers, and intrahepatic cholangiocarcinomas. The NOS scores of these studies ranged from 5 to 8 (mean: 6.33; [S1](#pone.0152674.s002){ref-type="supplementary-material"} and [S2](#pone.0152674.s003){ref-type="supplementary-material"} Tables), thus, the studies were of high quality.

10.1371/journal.pone.0152674.t001

###### Main characteristics of the eligible studies.

![](pone.0152674.t001){#pone.0152674.t001g}

  First author                                         Year   Region   Type of cancer                    Number of cases   Median age(range)   Adjuvant therapybefore surgery   Adjuvant therapy after surgery                             Follow-up (months)   NOS score
  ---------------------------------------------------- ------ -------- --------------------------------- ----------------- ------------------- -------------------------------- ---------------------------------------------------------- -------------------- -----------
  Huang YH \[[@pone.0152674.ref013]\]                  2013   China    Hepatocellular carcinoma          70                57(43--72)          NR                               NR                                                         68                   7
  He TY \[[@pone.0152674.ref014]\]                     2014   Taiwan   Colorectal cancer                 158               NR                  NR                               NR                                                         81                   5
  Bouchekioua-Bouzaghou K \[[@pone.0152674.ref017]\]   2014   France   Breast cancer                     154               57(27--87)          NR                               NR                                                         162                  7
  Shen Z \[[@pone.0152674.ref011]\]                    2002   China    Breast carcinoma                  116               53.7(32--77)        Radiotherapy for 40 cases        Chemotherapy for 56 cases, Hormonal therapy for 43 cases   70                   6
  Tsai LH \[[@pone.0152674.ref027]\]                   2014   Taiwan   Lung adenocarcinomas              115               NR                  None                             NR                                                         140                  7
  Jiang LL \[[@pone.0152674.ref015]\]                  2014   China    Non-small cell lung cancer        142               58.2(31--84)        None                             NR                                                         71                   7
  Yang JY \[[@pone.0152674.ref016]\]                   2015   China    Pancreatic ductaladenocarcinoma   205               NR                  None                             NR                                                         98                   7
  Calles A \[[@pone.0152674.ref028]\]                  2015   USA      Lung adenocarcinoma               126               63.5(30--84)        NR                               NR                                                         60                   7
  Wang JH \[[@pone.0152674.ref026]\]                   2015   China    Intrahepatic cholangiocarcinoma   326               NR                  NR                               NR                                                         99                   8
  Lee SW \[[@pone.0152674.ref018]\]                    2015   Taiwan   Hepatocellular carcinoma          120               NR                  NR                               NR                                                         101                  7
  Morton JP \[[@pone.0152674.ref012]\]                 2010   UK       Pancreatic cancer                 106               NR                  NR                               NR                                                         95                   6
  Ding XM \[[@pone.0152674.ref029]\]                   2005   China    Lung adenocarcinoma               62                60.5(32--77)        None                             Radiotherapy/chemotherapy                                  80                   8
  Yang XW \[[@pone.0152674.ref030]\]                   2012   China    Gastric cancer                    100               65(31--85)          None                             Radiotherapy/chemotherapy                                  36                   7
  Huang Y \[[@pone.0152674.ref031]\]                   2014   China    Gastric carcinoma                 115               61(37--80)          None                             NR                                                         75                   6

10.1371/journal.pone.0152674.t002

###### LKB1 evaluation and survival data of the selected studies.

![](pone.0152674.t002){#pone.0152674.t002g}

  First author                                         Test method   Staining position            Cut-off value                                                                             Outcome   Analysis method   HR and 95%CI
  ---------------------------------------------------- ------------- ---------------------------- ----------------------------------------------------------------------------------------- --------- ----------------- ---------------------
  Huang YH \[[@pone.0152674.ref013]\]                  IHC           Cytoplasm                    Staining index scores of ≤3                                                               OS        UA                3.155(1.603--6.211)
                                                                                                                                                                                                      MA                2.179(1.066--4.444)
                                                                                                                                                                                            DFS       UA                2.737(1.629--6.271)
  He TY \[[@pone.0152674.ref014]\]                     IHC           No specific description      A score equal to or lower than 100                                                        OS        UA                2.364(1.576--4.112)
                                                                                                                                                                                                      MA                3.146(1.876--5.276)
                                                                                                                                                                                            RFS       UA                2.522(1.701--4.445)
                                                                                                                                                                                                      MA                3.093(1.843--5.191)
  Bouchekioua-Bouzaghou K \[[@pone.0152674.ref017]\]   IHC           Nucleus                      Staining intensity recorded as 0                                                          OS        UA                1.417(0.722--2.704)
                                                                                                                                                                                            DFS       UA                1.279(0.732--2.225)
  Bouchekioua-Bouzaghou K \[[@pone.0152674.ref017]\]   IHC           Cytoplasm                    Staining intensity recorded as 0--1                                                       OS        UA                0.418(0.181--0.708)
                                                                                                                                                                                                      MA                0.403(0.199--0.820)
                                                                                                                                                                                            DFS       UA                0.495(0.249--0.809)
                                                                                                                                                                                                      MA                0.549(0.303--0.990)
  Shen Z \[[@pone.0152674.ref011]\]                    WB            Total protein                The bands of the breast cancer tissue in which the quantities were \<0.5                  OS        UA                3.754(1.899--10.75)
                                                                                                                                                                                            DFS       UA                2.529(1.383--5.933)
  Tsai LH \[[@pone.0152674.ref027]\]                   IHC           No specific description      A score equal to or lower than 100                                                        OS        UA                1.846(1.243--3.202)
                                                                                                                                                                                                      MA                1.868(1.160--3.007)
                                                                                                                                                                                            RFS       UA                1.828(1.247--3.122)
                                                                                                                                                                                                      MA                1.791(1.132--2.834)
  Jiang LL \[[@pone.0152674.ref015]\]                  IHC           Cytoplasm                    A score of 0--4                                                                           OS        UA                3.226(1.852--5.556)
                                                                                                                                                                                                      MA                2.128(1.136--4.000)
  Yang JY \[[@pone.0152674.ref016]\]                   IHC           No specific description      A total score \<4                                                                         OS        UA                2.278(1.495--3.472)
                                                                                                                                                                                                      MA                1.845(1.189--2.865)
  Calles A \[[@pone.0152674.ref028]\]                  IHC           Cytoplasm                    No staining                                                                               OS        UA                1.44(0.92--2.28)
  Wang JH \[[@pone.0152674.ref026]\]                   IHC           Cytoplasm                    The staining density was under the median value                                           OS        UA                1.857(1.498--2.483)
                                                                                                                                                                                                      MA                1.824(1.404--2.377)
  Lee SW \[[@pone.0152674.ref018]\]                    IHC           No specific description      The H-score was \<the median                                                              OS        UA                0.517(0.284--0.931)
                                                                                                                                                                                                      MA                0.496(0.245--1.047)
                                                                                                                                                                                            RFS       UA                0.403(0.237--0.624)
                                                                                                                                                                                                      MA                0.333(0.193--0.564)
  Morton JP \[[@pone.0152674.ref012]\]                 IHC           Cytoplasm                    The histoscore was ≤100                                                                   OS        UA                1.877(1.280--4.318)
                                                                                                                                                                                                      MA                1.87(1.09--3.22)
  Ding XM \[[@pone.0152674.ref029]\]                   IHC           Both nucleus and cytoplasm   The staining intensity in the neoplasms was lower than that of normal airway epithelium   OS        UA                3.003(2.524--9.635)
  Yang XW \[[@pone.0152674.ref030]\]                   IHC           Both nucleus and cytoplasm   The staining intensity in the neoplasms was less than that of normal mucosa               OS        UA                2.558(1.674--4.588)
  Huang Y \[[@pone.0152674.ref031]\]                   IHC           Both nucleus and cytoplasm   No staining                                                                               OS        UA                2.514(1.026--4.092)

Decreased LKB1 Expression and OS {#sec015}
================================

The pooled HR values revealed that decreased expression of LKB1 protein was significantly associated with OS in relation to solid tumors (HR: 1.86, 95%CI: 1.42--2.42, P\<0.001; [Fig 2](#pone.0152674.g002){ref-type="fig"}). Additionally, significant heterogeneity (I^2^ = 73.50%, P\<0.001) was observed when using a random-effects model to analyze the pooled HR values of the OSs. By successively omitting each study from the aggregated survival meta-analyses, a sensitivity analysis was performed to evaluate the influence of each individual study on the pooled HR. The results revealed that the pooled estimates of the effect of decreased LKB1 expression on the OS of patients with solid tumors did not vary substantially with the exclusion of any individual study, which implies that the results of this meta-analysis are stable ([Fig 3](#pone.0152674.g003){ref-type="fig"}).

![Forest plot describing the association between decreased LKB1 expression and OS.](pone.0152674.g002){#pone.0152674.g002}

![Sensitivity analysis of the OS in the meta-analysis (note: BB K was used as an abbreviation for Bouchekioua-Bouzaghou K because the full name was too long and affected the typesetting of the image).](pone.0152674.g003){#pone.0152674.g003}

To minimize heterogeneity, the subgroup analyses were performed according to the multivariate analysis, test method, region, cancer type, and staining position. Both of the subgroup analyses with the multivariate analysis method (HR: 1.55, 95%CI: 1.09--2.21, P = 0.015) and the IHC test method (HR: 1.79, 95%CI: 1.37--2.35, P\<0.001) demonstrated that decreased LKB1 expression was evidently related to poor OS in the patients with solid tumors, and the heterogeneities were similar. When stratifying by geographic region, decreased LKB1 expression was significantly associated with poor OS in patients from Asia (HR: 2.18, 95%CI: 1.66--2.86, P\<0.001 with less heterogeneity), while the non-Asian subgroup exhibited no association. When grouped according to cancer type, the pooled HRs for lung cancer and other solid tumors were 2.16 (95%CI: 1.47--3.18, P\<0.001 with more less heterogeneity) and 1.74 (95%CI: 1.23--2.45, P = 0.002), respectively. In the staining position subgroup, an intimate correlation between decreased LKB1 expression and poor OS was observed in both the cytoplasm studies (HR = 1.69, 95%CI: 1.07--2.68, P = 0.024) and another group (HR = 1.87, 95%CI: 1.30--2.68, P = 0.001), and significant heterogeneity was present ([Table 3](#pone.0152674.t003){ref-type="table"}).

10.1371/journal.pone.0152674.t003

###### Associations between decreased LKB1 expression and OS stratified according to the test method, geographic region, cancer type and staining position.
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  Categories              Subgroups     Reference number                                                                                                                                                            HR (95% CI)        P-Value   Heterogeneity   
  ----------------------- ------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------ --------- --------------- ---------
  **Test method**         IHC           \[[@pone.0152674.ref012]--[@pone.0152674.ref018], [@pone.0152674.ref026]--[@pone.0152674.ref031]\]                                                                          1.79(1.37--2.35)   \<0.001   74.2%           \<0.001
  **Region**              Asian         \[[@pone.0152674.ref011], [@pone.0152674.ref013]--[@pone.0152674.ref016], [@pone.0152674.ref027], [@pone.0152674.ref029]--[@pone.0152674.ref031]\]                          2.18(1.66--2.86)   \<0.001   67.1%           0.001
                          Not Asian     \[[@pone.0152674.ref012], [@pone.0152674.ref017], [@pone.0152674.ref028]\]                                                                                                  1.15(0.63--2.08)   0.647     75.1%           0.007
  **Cancer type**         Lung cancer   \[[@pone.0152674.ref015], [@pone.0152674.ref027]--[@pone.0152674.ref029]\]                                                                                                  2.16(1.47--3.18)   \<0.001   52.9%           0.095
                          Other types   \[[@pone.0152674.ref011], [@pone.0152674.ref013]--[@pone.0152674.ref018], [@pone.0152674.ref026], [@pone.0152674.ref030], [@pone.0152674.ref031]\]                          1.74(1.23--2.45)   0.002     78.1%           \<0.001
  **Staining position**   Cytoplasm     \[[@pone.0152674.ref012], [@pone.0152674.ref013], [@pone.0152674.ref015], [@pone.0152674.ref017], [@pone.0152674.ref026], [@pone.0152674.ref028]\]                          1.69(1.07--2.68)   0.024     80.4%           \<0.001
                          The others    \[[@pone.0152674.ref011], [@pone.0152674.ref014], [@pone.0152674.ref016]--[@pone.0152674.ref018],[@pone.0152674.ref027], [@pone.0152674.ref029]--[@pone.0152674.ref031]\]   1.87(1.30--2.68)   0.001     71.4%           0.001

Decreased LKB1 Expression and RFS/DFS {#sec016}
-------------------------------------

No significant correlation between decreased LKB1 expression and RFS was observed in the patients with solid tumors in either the univariate group (HR: 1.23, 95%CI: 0.41--3.67) or the multivariate group (HR: 1.23, 95% CI: 0.35--4.33) analysis in the random-effects model with significant heterogeneity (I^2^ = 93.70%, P\<0.001; I^2^ = 94.70%, P\<0.001, respectively). Moreover, the pooled HR from the univariate analysis method with a random-effects model also indicated that no significant association existed between decreased LKB1 expression and DFS (HR: 1.42, 95% CI: 0.65--3.10) ([Table 4](#pone.0152674.t004){ref-type="table"}).

10.1371/journal.pone.0152674.t004

###### Meta-analysis results of decreased LKB1 expression and survival.
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  Survival data   Analysis method         Reference number                                                                                     HR (95% CI)        P-value   Heterogeneity   
  --------------- ----------------------- ---------------------------------------------------------------------------------------------------- ------------------ --------- --------------- ---------
  **OS**          Univariate analysis     \[[@pone.0152674.ref011]--[@pone.0152674.ref018],[@pone.0152674.ref026]--[@pone.0152674.ref031]\]    1.86(1.42--2.42)   \<0.001   73.5%           \<0.001
                  Multivariate analysis   \[[@pone.0152674.ref012]--[@pone.0152674.ref018], [@pone.0152674.ref026], [@pone.0152674.ref027]\]   1.55(1.09--2.21)   0.015     76.5%           \<0.001
  **RFS**         Univariate analysis     \[[@pone.0152674.ref014], [@pone.0152674.ref018],[@pone.0152674.ref027]\]                            1.23(0.41--3.67)   0.709     93.7%           \<0.001
                  Multivariate analysis   \[[@pone.0152674.ref014], [@pone.0152674.ref018],[@pone.0152674.ref027]\]                            1.23(0.35--4.33)   0.746     94.7%           \<0.001
  **DFS**         Univariate analysis     \[[@pone.0152674.ref011], [@pone.0152674.ref013], [@pone.0152674.ref017]\]                           1.42(0.65--3.10)   0.376     83.5%           \<0.001

Correlations of Decreased LKB1 Expression with Clinicopath-Ological Features {#sec017}
----------------------------------------------------------------------------

The clinical and pathological parameters that were collected from the eligible studies are presented in [S3 Table](#pone.0152674.s004){ref-type="supplementary-material"}. Meanwhile, [Table 5](#pone.0152674.t005){ref-type="table"} summarizes the pooled results of the correlations that were identified between decreased LKB1 expression and the clinicopathological features in the patients with solid tumors. No significant correlations of decreased LKB1 expression with age, sex or tumor differentiation were observed. However, the decreased expression of LKB1 was positively associated with tumor size (OR: 1.60, 95%CI: 1.09--2.36, P = 0.017), lymph node metastasis (OR: 2.41, 95%CI: 1.53--3.78, P\<0.001) and TNM stage (OR: 3.35, 95%CI: 2.20--5.09, P\<0.001).

10.1371/journal.pone.0152674.t005

###### Meta-analysis results of the associations of decreased LKB1 expression with clinicopathological parameters.

![](pone.0152674.t005){#pone.0152674.t005g}

  Clinicopathological parameter             Reference number                                                                                                                                                                                     Overall OR(95% CI)   P-value   Heterogeneity test(Q, I^2^, P-value)
  ----------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------- --------- --------------------------------------
  **Age(≥60 vs \<60)**                      \[[@pone.0152674.ref015], [@pone.0152674.ref029]--[@pone.0152674.ref031]\]                                                                                                                           0.88(0.56--1.39)     0.583     1.74, 0.0%, 0.628
  **Sex(male vs female)**                   \[[@pone.0152674.ref013]--[@pone.0152674.ref016], [@pone.0152674.ref026]--[@pone.0152674.ref030]\]                                                                                                   0.90(0.71--1.16)     0.418     5.63, 0.0%, 0.689
  **Tumor differentiation(poor vs well)**   \[[@pone.0152674.ref011], [@pone.0152674.ref013], [@pone.0152674.ref015]--[@pone.0152674.ref017], [@pone.0152674.ref026], [@pone.0152674.ref030]\]                                                   1.84(0.79--4.30)     0.160     39.24, 82.2%, \<0.001
  **Tumor size(T3-4 vs T1-2)**              \[[@pone.0152674.ref011], [@pone.0152674.ref013], [@pone.0152674.ref016], [@pone.0152674.ref017], [@pone.0152674.ref026], [@pone.0152674.ref027], [@pone.0152674.ref029]--[@pone.0152674.ref031]\]   1.60(1.09--2.36)     0.017     17.11, 47.4%, 0.047
  **Lymph node metastasis(yes vs no)**      \[[@pone.0152674.ref011], [@pone.0152674.ref015]--[@pone.0152674.ref017], [@pone.0152674.ref026], [@pone.0152674.ref027], [@pone.0152674.ref029]--[@pone.0152674.ref031]\]                           2.41(1.53--3.78)     \<0.001   29.17, 69.2%, 0.001
  **TNM stage(III-IV vs I-II)**             \[[@pone.0152674.ref013]--[@pone.0152674.ref016], [@pone.0152674.ref026], [@pone.0152674.ref027], [@pone.0152674.ref029]--[@pone.0152674.ref031]\]                                                   3.35(2.20--5.09)     \<0.001   18.28, 56.2%, 0.019

Evaluation of Publication Bias {#sec018}
------------------------------

The shape of the funnel plot for the OS appeared to asymmetrical, indicating potential publication bias ([Fig 4](#pone.0152674.g004){ref-type="fig"}). However, the Begg's and Egger's tests revealed non-significant values (P = 0.322 and 0.928, respectively).

![Funnel plot for the assessment of potential publication bias regarding OS in the meta-analysis.](pone.0152674.g004){#pone.0152674.g004}

Discussion {#sec019}
==========

LKB1 is a primary upstream kinase of adenosine monophosphate-activated protein kinase (AMPK) \[[@pone.0152674.ref032]\] and a required element in cell metabolism for the maintenance of energy homeostasis. LKB1 exerts growth-suppressing effects by activating a group of AMPK-related kinases. The activation of AMPK-related kinases by LKB1 plays vital roles in the maintenance of cell polarity and inhibits the inappropriate expansion of cancer cells. Thus, LKB1 functions as a human tumor suppressor \[[@pone.0152674.ref033],[@pone.0152674.ref034]\]. Consequently, decreases in LKB1 can promote cancer progression and are predictive of poor prognoses in patients with cancer \[[@pone.0152674.ref016],[@pone.0152674.ref035]\]. However, thus far, no meta-analyses have been performed to evaluate the prognostic value of decreased LKB1 in patients with solid tumors. To the best of our knowledge, this is the first comprehensive meta-analysis of the effects of decreased LKB1 expression on the survival and clinicopathological characteristics of solid tumors.

In this meta-analysis, 14 eligible studies met the inclusion criteria. The data were organized according to OS, RFS and DFS. The combined results demonstrated that decreased LKB1 expression was associated with a poorer OS in solid tumor patients based on a random effects model. The sensitivity analysis revealed that no individual study influenced the overall results, indicating the stability of the pooled results. Additionally, no publication bias was observed. Due to significant heterogeneity between our included studies, we performed further subgroup analyses according to the analysis method, test method, region, cancer type, and staining position. With the exception of non-Asian regions, all of the subgroup analyses indicated that decreased LKB1 expression was associated with poor OS. Regarding the studies that evaluated RFS and DFS, decreased expression of LKB1 was not correlated with either of these factors. However, because the number of articles related to the analyses of RFS and DFS were both no more than 3, these results remain inconclusive and require further investigation. Furthermore, significant associations of decreased LKB1 expression with larger tumor size, lymph node metastasis and higher TNM stage were observed. Therefore, we conclude that decreased LKB1 may serve as a biomarker for poor clinicopathological prognostic factors.

The current analyses have several important implications. First, decreased LKB1 may be a universal poor prognostic marker in solid tumors. In this meta-analysis, we included seven different cancer types, i.e., lung cancer \[[@pone.0152674.ref015],[@pone.0152674.ref027]--[@pone.0152674.ref029]\], breast cancer \[[@pone.0152674.ref011],[@pone.0152674.ref017]\], gastric cancer \[[@pone.0152674.ref030],[@pone.0152674.ref031]\], hepatocellular cancer \[[@pone.0152674.ref013],[@pone.0152674.ref018]\], pancreatic cancer \[[@pone.0152674.ref012],[@pone.0152674.ref016]\], colorectal cancer \[[@pone.0152674.ref014]\] and intrahepatic cholangiocarcinoma \[[@pone.0152674.ref026]\]. The pooled results from these cancer types demonstrated that decreased LKB1 expression was associated with a poor OS and this finding can basically be extended to all solid tumors \[[@pone.0152674.ref022],[@pone.0152674.ref036]--[@pone.0152674.ref038]\]. Second, we demonstrated that decreased LKB1 correlated with poor OS in the Asian region but not in the non-Asian region. This discrepancy may have been due to environmental factors that varied in the different regions and different genetic backgrounds \[[@pone.0152674.ref039],[@pone.0152674.ref040]\]. Third, decreased LKB1 expression may be a reliable prognostic marker of lung cancer patients with poor OS. Our analysis results revealed that lung cancer patients with decreased expression of LKB1 exhibited significantly poorer OSs. However, because lung cancer is the leading cause of cancer-related death worldwide \[[@pone.0152674.ref041]\], additional original research regarding the correlation between decreased LKB1 expression and the survival data of patients with lung cancer is needed to verify our results. Fourth, different localizations and specific mutations of LKB1 may alter the association between LKB1 expression and cancer patient survival. LKB1 has different localizations in mammalian cells. The accumulation of LKB1has been detected in both the nuclei and cytoplasm of cells \[[@pone.0152674.ref042],[@pone.0152674.ref043]\]. Via the formation of complexes with other proteins \[[@pone.0152674.ref043],[@pone.0152674.ref044]\] and under specific conditions \[[@pone.0152674.ref045],[@pone.0152674.ref046]\], LKB1 can also translocate from the nucleus to the cytoplasm. Additionally, specific mutations can lead to the loss of the ability of LKB1 to inhibit cell growth and promote cancer progression \[[@pone.0152674.ref047],[@pone.0152674.ref048]\]. Thus, the possible mutations in LKB1 maybe among the reasons for the conflicting OS results that included in our meta-analysis.

However, in our meta-analysis, two studies reported inconsistent results that decreased LKB1 might correlate with a favorable survival \[[@pone.0152674.ref017],[@pone.0152674.ref018]\], which showing the two obvious outliers on the left of graph in [Fig 4](#pone.0152674.g004){ref-type="fig"}. We suspect, aside from the possibility of different localizations and specific mutations of LKB1 discussed above, that the particular molecular phenotypes, such as methylated ERα(metERα) \[[@pone.0152674.ref017]\] and Skp2-dependent ubiquitination \[[@pone.0152674.ref018]\], as well as its related mechanisms, of the metERα/Src/PI3K complex \[[@pone.0152674.ref017]\] and the Skp2-mediated K63-linked polyubiquitination of LKB1 \[[@pone.0152674.ref018]\] may play primary roles in these contradictory phenomena.

Several limitations should be considered when interpreting our meta-analysis results. One of the main limitations is the significant heterogeneity between the included studies. However, we used a random-effects model with the pooled data. The heterogeneity among these studies could be explained by the different patient characteristics or differences in the specific study designs according to the different tumor types. Another limitation is that some of the survival data were extracted from Kaplan-Meier curves and might have introduced bias. Thus, the present statistics seem to be less reliable than those directly obtained from published studies. One additional limitation is that all of the included studies were designed as retrospective studies, and such studies are more likely to be published if they have positive results than if they have negative results. Therefore, our estimate of the association between decreased LKB1 and outcome may have been overestimated. Finally, the lack of consensus regarding the definition of the cut-off value for decreased LKB1 expression in these included studies might have led to between-study heterogeneity, and we were unable to set a baseline for decreased LKB1 expression which may have resulted in inconsistency.

In summary, this meta-analysis suggested that decreased LKB1 expression significantly contributed to poor OS in solid tumor patients. Decreased LKB1 is also a potential predictive marker for poor clinicopathological prognostic factors in patients with solid tumors. However, further studies related to specific tumor types and perspectives are required to verify the clinical utility of decreased LKB1 in solid tumors.
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